Kinetic myotropes are precision cardiovascular therapeutics that optimize sarcomere mechanics to safely enhance cardiac contractility without elevating intracellular calcium. Unlike legacy inotropes that force the heart to overwork, kinetic myotropes boost systolic force while preserving crucial diastolic relaxation, completely avoiding the cellular ATP tax and pro-arrhythmic risks.

In Acute Decompensated Heart Failure (ADHF), this mechanism is transformative. It safely pulls crashing patients back from the hemodynamic cliff by instantly restoring forward flow and organ perfusion, offering a rapid-rescue IV intervention that stabilizes the ICU patient without the fatal toxicity of current standards of care.

Milestones: (1) Intravenous (IV) readiness package; (2) Functional cardiotoxicity de-risking; (3) Rat model - Pharmacokinetics (PK)